Avidor Shulman

Avidor has served as Biond’s CTO since its inception and has over 20 years of experience in applied R&D, including all aspects of product development, innovation management & entrepreneurship. Prior to Biond, Avidor was Senior Director of Protein Chemistry at Protalix Biotherapeutics (NASDAQ: PLX) where he established the Protein Chemistry department. Avidor and his team led the development of Protalix’ pipeline of ‘Bio-Better’ products by implementing chemistry tools on biologics. Avidor was instrumental in the development of pegunigalsidase alfa, a breakthrough chemically modified enzyme replacement therapy for Fabry Disease currently awaiting FDA approval, and played a pivotal part in all CMC and regulatory efforts leading to its BLA submission. Avidor served as Director of Innovation at Enzymotec before joining Protalix. He holds a Ph.D. in organic chemistry from the Technion – Israel Institute of Technology and has spent most of his professional career on the interface between chemistry and biology.